# OnCo record resistance-routes-map (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/resistance-routes-map/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "resistance-routes-map" ;
  schema:name "Resistance routes: how a blocked pathway comes back"@en ;
  schema:description "When a drug blocks a cancer's engine, the cancer has five ways back: change the part the drug binds, make more of it, take a side road, switch to a different engine altogether, or stop letting the drug in. Knowing which route a tumour took decides the next drug."@en ;
  schema:url <https://onco.cc/pathways/resistance-routes-map/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Drug_resistance> ;
  schema:citation <https://doi.org/10.1038/s41586-019-1730-1> ;
  onco:tag "mechanism", "mechanics-atlas" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/estrogen-receptor/>, <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/btk/>, <https://onco.cc/targets/bcr-abl/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/dll3/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/asciminib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/elacestrant/>, <https://onco.cc/drugs/tarlatamab/> ;
  onco:pathways <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/clonal-evolution/>, <https://onco.cc/pathways/drug-tolerant-persisters/>, <https://onco.cc/pathways/drug-efflux-pumps/>, <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/> ;
  onco:terms <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/c797s/>, <https://onco.cc/terms/met-amplification/>, <https://onco.cc/terms/esr1-mutation/>, <https://onco.cc/terms/ar-v7/>, <https://onco.cc/terms/efflux-pump/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/oligoprogression/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-vasan-nature/> .